Beneficial response to anakinra and thalidomide in Schnitzler's syndrome - Wikidata - wikimedia - TriplyDB

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

http://www.wikidata.org/entity/Q24675386

about

Schnitzler's syndrome: lessons from 281 cases The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome Biologics in dermatologic therapy - an update.Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Why not treat human cancer with interleukin-1 blockade?Schnitzler syndrome with cold-induced urticaria The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.An expanding role for interleukin-1 blockade from gout to cancer.Autoinflammation: translating mechanism to therapy.Therapy of autoinflammatory syndromes.The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome.The spectrum of autoinflammatory diseases: recent bench to bedside observations Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Schnitzler's syndrome: successful treatment with anakinra.Autoinflammatory syndromes with a dermatological perspective.Schnitzler's syndrome: a case report.Schnitzler syndrome: an under-diagnosed clinical entity.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.NOD-like receptors and inflammation.Treating inflammation by blocking interleukin-1 in humans.Inflammasome and IL-1beta-mediated disorders Regulation of inflammasome activity.Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature.Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response.Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.Pattern recognition receptors in immune disorders affecting the skin.Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist.A rare cause of a common symptom, Anakinra is effective in the urticaria of Schnitzler Syndrome: a case report.Mullins' syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra Schnitzler's syndrome: a diagnostic conundrum.Anakinra in the treatment of rheumatic disease.Dysfunctional inflammasome in Schnitzler's syndrome.Kidney involvement in the Schnitzler syndrome, a rare disease.An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.

P2860

Q21195864-4F7164A4-25C6-4B99-B010-EFDC40677F84 Q28070297-D0519B85-5D84-40BB-9C61-2FC68882ED26 Q33607620-3F90657E-27F7-47F2-8895-CC82F36687BF Q33710807-46022F54-8936-4685-874A-CCF1727AA888 Q33833871-12DA34AE-E847-41B7-9396-836E5D116268 Q34212996-DCC89FD0-4CC8-450F-B66B-8DC389DC1DD0 Q34504770-DA1558AB-F3B8-4667-8336-5825C7778942 Q35016951-5623AE07-73D3-42C4-9254-ED78F8B0B045 Q35016969-478F8D82-F089-4264-86A5-B469772B5B8F Q35122583-DE780408-68FB-44FD-BE9A-93BD24CBA236 Q35219001-BB22E2A3-CEE1-4BA0-9E28-4D88B0FFA249 Q35558406-B3C99287-F491-4758-858A-90BAA227A725 Q35868028-DEC19461-D121-4079-8F01-6AA61B78AB3D Q35879125-0B095088-C36C-45D5-A790-A75240636317 Q36048259-F3A07AA5-3A15-4940-A554-7B71A7B427A6 Q36126508-0DAF17C1-C98F-43D3-8C4B-6F72231495AC Q36816872-51DF2A47-08CD-4CAA-AFB9-58F2A1AFE1EB Q36903081-34F93FC7-ACBE-4359-B080-D33A18F91DC7 Q36922302-023E8D9A-D5F4-49E6-8446-3DE0A676C5FD Q36949902-95CF982B-0519-4279-8D27-CCB3AFA9C47A Q37212707-9327AADF-EFFB-45DA-B8D0-E837310CA483 Q37270409-D5CFFC02-8CB8-47BA-89E3-760255676545 Q37353179-7FC48B32-BBC1-407E-9A92-07847FA51E93 Q37636664-5C1C257A-5619-426A-9DAF-7A74C04E605F Q37738096-35B6406B-4D52-470D-A324-B75F7CB4669F Q37750913-AE39876E-188D-4AE6-8868-7769CB93B5E8 Q37799379-5031BCC0-52BF-4C5D-8ACC-7717D33E12FE Q37811988-E6F71DA0-3BC1-4A5F-9358-2392A67EAECC Q37979862-F904F33F-9469-4CA7-8C5E-4F2504C54FAD Q37991471-E2765421-E7C8-4FA6-9F9D-FD06988B80EE Q40270754-6EECD00E-E32C-450C-BAC8-3DE88CAE4FDA Q40384524-5981A47A-2A74-4BB4-81BE-BFB6D3B1E959 Q40404340-93E644B2-0AA5-4910-A1A1-2CCF5E35AE2E Q41210551-D711C29D-33A4-4284-8D1F-60D202DB2ECF Q42717455-22FC8EEF-7785-4F09-8CAE-E5328C88B2FA Q43061720-F1A8E0C6-C546-4C24-A3D2-CD4F81464B4B Q43288641-75E14521-6F21-47AE-A001-4D24ACB1F0FC Q49294603-B749F403-C17F-4177-ABE0-2104ADA795C3 Q52850152-87EB8011-2794-44C2-99D2-7301F61B393D

P2860

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

http://www.wikidata.org/entity/Q24675386

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@ast

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@en

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@nl

type

label

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@ast

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@en

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@nl

prefLabel

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@ast

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@en

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@nl

P1433

Q24675386-CDA5A782-1365-4E33-8953-CC28D450CB72

P1476

Q24675386-D5A66579-D7D3-45D7-8424-228ACE5299D1

P2093

Q24675386-356E5644-89B3-42E8-8F2C-394BFF21C53E

Q24675386-4EF1ED48-B9DA-4A5B-AD4E-E2FD5DE5657A

Q24675386-D79AFA8D-4377-4B2D-A1BF-68D17A9F5720

Q24675386-E51F7F16-884F-4BE0-B894-86477045DA10

Q24675386-FB4AEBF5-E570-4C9B-82A9-384CE41788F7

P2860

Q24675386-0500B492-9CF1-4484-9E8A-A2C9D1A21A1E

Q24675386-0A32F67D-DBA8-4450-940E-DE55A6B9550C

Q24675386-177D4F14-B4EB-4E6B-A293-90863AD5C1FE

Q24675386-2CDF6779-3BF8-4F16-B22E-42EEBC4EFF34

Q24675386-33B82C9C-2D18-4939-96ED-A2380561A472

Q24675386-3F102432-1CD9-48C0-8649-BADB01ECE5CC

Q24675386-52C7E743-BDF3-44A8-83E5-5711CE461660

Q24675386-77338C58-163B-448A-99A1-7618CD618869

Q24675386-7D0103B0-0B69-4274-B110-8C6B8F3137CA

Q24675386-B9D2CEC4-F848-4BEA-861A-2934A6625028

P304

Q24675386-C1ECCE95-2965-4386-97C5-DDEE4A2CB142

P31

Q24675386-48f97647-1f85-4154-9e02-6dc880cd4d61

Q24675386-5DD5BCB2-904E-486B-B545-0A2749C6E9CA

P356

Q24675386-9223E869-09A5-4EBA-AC0B-5F6626B8ADEF

P407

Q24675386-CCB13688-F1F2-4EE6-A3C7-A75262CC65D3

P433

Q24675386-C198B069-368C-4CC6-A9F7-DE5B45408DFE

P478

Q24675386-55461199-331B-4EF2-AEC1-9AB80DE84A39

P50

Q24675386-AF51C149-9806-4370-9D44-BCE86218B8CE

P577

Q24675386-81DED8E0-3CE6-4D8F-BB04-02EC0BD8AE55

P5875

Q24675386-728F2558-076E-41FF-804D-F88F94FE3B45

P698

Q24675386-E2BAE02A-B7BB-470E-8C5B-EA729C6ECEB7

P921

Q24675386-7516758F-479B-4620-A0AF-3E53B81179E4

P932

Q24675386-AD688BAD-4A35-439D-B40C-6D2D212DCE55

P356

ARD.2005.045245

P1433

Annals of the Rheumatic Diseases

P1476

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

@en

P2093

E J Bodar

http://www.w3.org/2001/XMLSchema#string

H D de Koning

http://www.w3.org/2001/XMLSchema#string

J C H van der Hilst

http://www.w3.org/2001/XMLSchema#string

J W M van der Meer

http://www.w3.org/2001/XMLSchema#string

M G Netea

http://www.w3.org/2001/XMLSchema#string

P2860

The Schnitzler syndrome. Four new cases and review of the literature.

Schnitzler's syndrome with IgG kappa gammopathy.

Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.

Schnitzler's syndrome with monoclonal IgG kappa gammopathy: good response to cyclosporin.

Schnitzler syndrome: heterogeneous immunopathological findings involving IgM-skin interactions.

Schnitzler's syndrome presenting as fever of unknown origin (FUO). The role of cytokines in its systemic features.

A case of urticarial vasculitis associated with macroglobulinemia (Schnitzler's syndrome).

Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution, and receptor-binding inhibition--higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia).

Schnitzler's syndrome: successful treatment of two patients using thalidomide.

P304

542-544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2005.045245

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7664752

http://www.w3.org/2001/XMLSchema#string

P698

16096327

http://www.w3.org/2001/XMLSchema#string

P921

P932

1798111

http://www.w3.org/2001/XMLSchema#string